Drug Profile
Edaravone/(+)-2-nonanol - Beijing Tiantan Hospital/Yantai Yene Pharma
Alternative Names: (+)-2-nonanol/edaravone; adaravone and borneol sublingual tablet; Y 2; Y-2 sublingual tabletsLatest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Beijing Tian Tan Hospital; YenePharma
- Developer YenePharma
- Class Anti-inflammatories; Antihaemorrhagics
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Stroke
- No development reported Haemorrhage
Most Recent Events
- 05 Dec 2023 Simcere Pharmaceutical completes a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA (NCT05940883)
- 06 Sep 2023 Simcere Pharmaceutical initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA (NCT05940883)
- 11 Jul 2023 Simcere Pharmaceutical plans a phase I pharmacokinetic trial in healthy volunteers (PO, Tablet) in USA, in July 2023 (NCT05940883)